Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Stem Cell Res ; 65: 102951, 2022 12.
Artigo em Inglês | MEDLINE | ID: mdl-36332467

RESUMO

Dilated cardiomyopathy (DCM) is a progressive heart muscle disease that can culminate with heart failure and death. Mutations in several genes can cause DCM, including hyperpolarization-activated cyclic nucleotide-gated channel (HCN4), which has a critical function in the autonomic control of the heart rate. Here, we generated two human induced pluripotent stem cell (iPSC) lines generated from two DCM patients carrying variants in the HCN4 gene (c.2587G > T and c.2846G > A). Both lines display normal karyotype, typical morphology of pluripotent stem cells, and differentiate into all three germ layers in vitro. These lines are valuable resources for studying the pathological mechanisms of DCM.


Assuntos
Cardiomiopatia Dilatada , Células-Tronco Pluripotentes Induzidas , Humanos , Cardiomiopatia Dilatada/genética , Proteínas Musculares/genética , Canais de Potássio/genética , Canais Disparados por Nucleotídeos Cíclicos Ativados por Hiperpolarização/genética
2.
Stem Cell Res ; 59: 102638, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34954454

RESUMO

LMNA-related dilated cardiomyopathy (DCM) is caused by pathogenic variants in LMNA and is characterized by left ventricular enlargement, reduced systolic function, and arrhythmia. Here, we generated three human induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells (PBMCs) of three DCM patients carrying the same single heterozygous mutation, c.1129C > T, in LMNA. All lines expressed normal iPSC morphology, high levels of pluripotent markers, normal karyotypes, and could differentiate into the three germ layers. These iPSC lines can serve as invaluable tools to model pathological mechanisms of DCM in vitro caused by LMNA mutations.

4.
Circ Heart Fail ; 4(6): 692-9, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21908586

RESUMO

BACKGROUND: Although much is known about the risk factors for poor outcome in patients hospitalized with acute heart failure and left ventricular dysfunction, much less is known about the syndrome of acute heart failure primarily affecting the right ventricle (acute right heart failure). METHODS AND RESULTS: By using Stanford Hospital's pulmonary hypertension database, we identified consecutive acute right heart failure hospitalizations in patients with PAH. We used longitudinal regression analysis with the generalized estimating equations method to identify factors associated with an increased likelihood of 90-day mortality or urgent transplantation. From June 1999 to September 2009, 119 patients with PAH were hospitalized for acute right heart failure (207 episodes). Death or urgent transplantation occurred in 34 patients by 90 days of admission. Multivariable analysis identified a higher respiratory rate on admission (>20 breaths per minute; OR, 3.4; 95% CI, 1.5-7.8), renal dysfunction on admission (glomerular filtration rate <45 mL/min per 1.73 m2; OR, 2.7; 95% CI, 1.2-6.3), hyponatremia (serum sodium ≤136 mEq/L; OR, 3.6; 95% CI, 1.7-7.9), and tricuspid regurgitation severity (OR, 2.5 per grade; 95% CI, 1.2-5.5) as independent factors associated with an increased likelihood of death or urgent transplantation. CONCLUSIONS: These results highlight the high mortality after hospitalizations for acute right heart failure in patients with PAH. Factors identifiable within hours of hospitalization may help predict the likelihood of death or the need for urgent transplantation in patients with PAH.


Assuntos
Insuficiência Cardíaca/epidemiologia , Insuficiência Cardíaca/mortalidade , Hospitalização , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/mortalidade , Doença Aguda , Adulto , Comorbidade , Feminino , Seguimentos , Taxa de Filtração Glomerular/fisiologia , Insuficiência Cardíaca/fisiopatologia , Humanos , Hipertensão Pulmonar/fisiopatologia , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Mecânica Respiratória/fisiologia , Estudos Retrospectivos , Fatores de Risco , Sódio/sangue , Taxa de Sobrevida
5.
Circ Heart Fail ; 3(3): 395-404, 2010 May.
Artigo em Inglês | MEDLINE | ID: mdl-20176716

RESUMO

BACKGROUND: Cardiac resynchronization therapy improves morbidity and mortality in appropriately selected patients. Whether atrioventricular (AV) and interventricular (VV) pacing interval optimization confers further clinical improvement remains unclear. A variety of techniques are used to estimate optimum AV/VV intervals; however, the precision of their estimates and the ramifications of an imprecise estimate have not been characterized previously. METHODS AND RESULTS: An objective methodology for quantifying the precision of estimated optimum AV/VV intervals was developed, allowing physiologic effects to be distinguished from measurement variability. Optimization using multiple conventional techniques was conducted in individual sessions with 20 patients. Measures of stroke volume and dyssynchrony were obtained using impedance cardiography and echocardiographic methods, specifically, aortic velocity-time integral, mitral velocity-time integral, A-wave truncation, and septal-posterior wall motion delay. Echocardiographic methods yielded statistically insignificant data in the majority of patients (62%-82%). In contrast, impedance cardiography yielded statistically significant results in 84% and 75% of patients for AV and VV interval optimization, respectively. Individual cases demonstrated that accepting a plausible but statistically insignificant estimated optimum AV or VV interval can result in worse cardiac function than default values. CONCLUSIONS: Consideration of statistical significance is critical for validating clinical optimization data in individual patients and for comparing competing optimization techniques. Accepting an estimated optimum without knowledge of its precision can result in worse cardiac function than default settings and a misinterpretation of observed changes over time. In this study, only impedance cardiography yielded statistically significant AV and VV interval optimization data in the majority of patients.


Assuntos
Nó Atrioventricular/fisiopatologia , Estimulação Cardíaca Artificial/métodos , Cardioversão Elétrica/métodos , Insuficiência Cardíaca/fisiopatologia , Insuficiência Cardíaca/terapia , Idoso , Idoso de 80 Anos ou mais , Cardiografia de Impedância , Desfibriladores Implantáveis , Ecocardiografia Doppler , Feminino , Insuficiência Cardíaca/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Marca-Passo Artificial , Tempo de Reação/fisiologia , Reprodutibilidade dos Testes , Volume Sistólico/fisiologia
6.
Cardiol Res Pract ; 2011: 568918, 2010 Dec 22.
Artigo em Inglês | MEDLINE | ID: mdl-21234100

RESUMO

Background. Currently there are no reliable predictors of response to cardiac resynchronization therapy (CRT) before implantation. We compared pre-CRT left ventricular (LV) dyssynchrony by tissue Doppler imaging (TDI) and regional volumetric analysis by 3-dimensional transthoracic echocardiography (3DTTE) in predicting response to CRT. Methods. Thirty-eight patients (79% nonischemic cardiomyopathy) with symptomatic heart failure who underwent CRT were enrolled. Clinical and echocardiographic responses were defined as improvement in one NYHA class and reduction in LV end-systolic volume by ≥15% respectively. Functional status was assessed by Minnesota Living with Heart Failure questionnaire and 6-minute walk distance. Results. In 33 patients, after CRT for 7.86 ± 2.27 months, there were 24 (73%) clinical and 19 (58%) echocardiographic responders. Functional parameters, LV dimensions, volumes and synchrony by TDI and 3DTTE improved significantly in responders. There was no difference in the number of responders and nonresponders when cut-off values for dyssynchrony by different measurements validated in other trials were applied. Area under receiver-operating-characteristic curve ranged from 0.4 to 0.6. Conclusion. CRT improves clinical and echocardiographic parameters in patients with systolic heart failure. The dyssynchrony measurements by TDI and 3DTTE are not comparable and are unable to predict response to CRT.

7.
Echocardiography ; 26(7): 759-65, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19558521

RESUMO

BACKGROUND: Responders to cardiac resynchronization therapy (CRT) have greater left ventricular (LV) dyssynchrony than nonresponders prior to CRT. AIM: We conducted this study to see whether the long term responders have more worsening of LV dyssynchrony and LV function on acute interruption of CRT. MATERIALS AND METHODS: We identified 22 responders and 13 nonresponders who received CRT as per standard criteria for 23.73 +/- 7.9 months (median 24.5 months). We assessed the acute change in LV function, mitral regurgitation (MR) and compared LV dyssynchrony in CRT on and off modes. RESULTS: On turning off CRT, there was no significant worsening of LV dyssynchrony in both responders and nonresponders. The dyssynchrony measurements by SPWMD, TDI and 3D echocardiography did not correlate significantly. LVESV increased (p = 0.02) and MR (p = 0.01) worsened in CRT-off mode in responders only without significant change in LVEF or LV dimensions. DISCUSSION AND CONCLUSION: In long-term responders to CRT, there is alteration in the function of remodeled LV with acute interruption of CRT, without significant worsening of LV dyssynchrony. The role of different echocardiographic parameters in the assessment of LV dyssynchrony remains controversial. Even after long-term CRT reversely remodels the LV, the therapy needs to be continued uninterrupted for sustained benefits.


Assuntos
Estimulação Cardíaca Artificial/efeitos adversos , Insuficiência da Valva Mitral/diagnóstico por imagem , Insuficiência da Valva Mitral/etiologia , Volume Sistólico , Disfunção Ventricular Esquerda/diagnóstico por imagem , Disfunção Ventricular Esquerda/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Insuficiência da Valva Mitral/prevenção & controle , Resultado do Tratamento , Ultrassonografia , Disfunção Ventricular Esquerda/prevenção & controle
8.
J Heart Lung Transplant ; 28(5): 527-30, 2009 May.
Artigo em Inglês | MEDLINE | ID: mdl-19416787

RESUMO

Chest pain is a common complaint in patients with pulmonary arterial hypertension (PAH). Left main coronary artery (LMCA) compression by an enlarged pulmonary artery trunk (PAT) has been associated with angina, but appropriate diagnostic and treatment approaches remain poorly defined. We present two cases of angina caused by LMCA compression from an enlarged pulmonary artery, one of which also presented with new, severe left ventricular systolic dysfunction attributed to myocardial ischemia. Diagnosis of LMCA stenosis was made via coronary angiography followed by computed tomography-gated coronary angiography (CT-CA), which confirmed pulmonary artery enlargement as the source of extrinsic compression. Restoring LMCA patency with percutaneous intervention and/or aggressive treatment of pulmonary hypertension led to significant improvement in angina, cardiac function and quality of life. Given the negative impact on cardiac function, prompt diagnosis and treatment of extrinsic LMCA compression should be considered a priority.


Assuntos
Angina Pectoris/etiologia , Estenose Coronária/etiologia , Hipertensão Pulmonar/complicações , Artéria Pulmonar , Adulto , Angina Pectoris/diagnóstico , Angina Pectoris/terapia , Angioplastia Coronária com Balão , Angiografia Coronária , Estenose Coronária/diagnóstico , Estenose Coronária/terapia , Ecocardiografia , Epoprostenol/uso terapêutico , Humanos , Hipertensão Pulmonar/diagnóstico , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/diagnóstico , Isquemia Miocárdica/etiologia , Isquemia Miocárdica/terapia , Piperazinas/uso terapêutico , Purinas/uso terapêutico , Citrato de Sildenafila , Stents , Sulfonas/uso terapêutico , Tomografia Computadorizada por Raios X , Ultrassonografia de Intervenção , Vasodilatadores/uso terapêutico
9.
Am Heart J ; 155(5): 889.e1-6, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18440337

RESUMO

BACKGROUND: Rapamycin has been shown to reduce anatomical evidence of cardiac allograft vasculopathy, but its effect on coronary artery physiology is unknown. METHODS: Twenty-seven patients without angiographic evidence of coronary artery disease underwent measurement of fractional flow reserve (FFR), coronary flow reserve (CFR), and the index of microcirculatory resistance (IMR) within 8 weeks and then 1 year after transplantation using a pressure sensor/thermistor-tipped guidewire. Measurements were compared between consecutive patients who were on rapamycin for at least 3 months during the first year after transplantation (rapamycin group, n = 9) and a comparable group on mycophenolate mofetil (MMF) instead (MMF group, n = 18). RESULTS: At baseline, there was no significant difference in FFR, CFR, or IMR between the 2 groups. At 1 year, FFR declined significantly in the MMF group (0.87 +/- 0.06 to 0.82 +/- 0.06, P = .009) but did not change in the rapamycin group (0.91 +/- 0.05 to 0.89 +/- 0.04, P = .33). Coronary flow reserve and IMR did not change significantly in the MMF group (3.1 +/- 1.7 to 3.2 +/- 1.0, P = .76; and 27.5 +/- 18.1 to 19.1 +/- 7.6, P = .10, respectively) but improved significantly in the rapamycin group (2.3 +/- 0.8 to 3.8 +/- 1.4, P < .03; and 27.0 +/- 11.5 to 17.6 +/- 7.5, P < .03, respectively). Multivariate regression analysis revealed that rapamycin therapy was an independent predictor of CFR and FFR at 1 year after transplantation. CONCLUSION: Early after cardiac transplantation, rapamycin therapy is associated with improved coronary artery physiology involving both the epicardial vessel and the microvasculature.


Assuntos
Doença da Artéria Coronariana/tratamento farmacológico , Vasos Coronários/efeitos dos fármacos , Transplante de Coração , Imunossupressores/farmacologia , Ácido Micofenólico/análogos & derivados , Sirolimo/farmacologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ácido Micofenólico/farmacologia , Transplante Homólogo , Resultado do Tratamento
10.
J Am Coll Cardiol ; 51(5): 560-5, 2008 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-18237685

RESUMO

OBJECTIVES: The objective of this study is to evaluate the predictive value of the index of microcirculatory resistance (IMR) in patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). BACKGROUND: Despite adequate epicardial artery reperfusion, a number of patients with STEMI have a poor prognosis because of microvascular damage. Assessing the status of the microvasculature in this setting remains challenging. METHODS: In 29 patients after primary PCI for STEMI, IMR was measured with a pressure sensor/thermistor-tipped guidewire. The Thrombolysis In Myocardial Infarction (TIMI) myocardial perfusion grade, TIMI frame count, coronary flow reserve, and ST-segment resolution were also recorded. RESULTS: The IMR correlated significantly with the peak creatinine kinase (CK) (R = 0.61, p = 0.0005) while the other measures of microvascular dysfunction did not. In patients with an IMR greater than the median value of 32 U, the peak CK was significantly higher compared with those having values 32 U compared with

Assuntos
Angioplastia Coronária com Balão , Circulação Coronária/fisiologia , Infarto do Miocárdio/fisiopatologia , Resistência Vascular , Creatina Quinase/metabolismo , Ecocardiografia , Eletrocardiografia , Feminino , Humanos , Masculino , Microcirculação/fisiologia , Pessoa de Meia-Idade , Infarto do Miocárdio/terapia , Miocárdio/patologia , Prognóstico , Função Ventricular Esquerda
11.
J Am Coll Cardiol ; 50(19): 1835-40, 2007 Nov 06.
Artigo em Inglês | MEDLINE | ID: mdl-17980248

RESUMO

OBJECTIVES: Our purpose was to evaluate the impact of nesiritide on renal function in patients with acute decompensated heart failure and baseline renal dysfunction. BACKGROUND: Although nesiritide is approved for the treatment of acute decompensated heart failure, retrospective analyses have raised concerns that it may cause worsened renal function. To date, no randomized clinical trials have prospectively evaluated this issue. METHODS: Consecutive patients with acute decompensated heart failure and baseline renal dysfunction were enrolled in this randomized, double-blind, placebo-controlled clinical trial. Subjects were randomized to receive nesiritide (0.01 microg/kg/min with or without a 2-microg/kg bolus) or placebo (5% dextrose in water) for 48 h in addition to their usual care. Predefined primary end points of the trial were a rise in serum creatinine by > or =20% and change in serum creatinine. RESULTS: Seventy-five patients were enrolled (39 nesiritide, 36 placebo). The groups had similar baseline age (74.9 vs. 75.5 years, respectively), blood pressure (123/64 vs. 125/64 mm Hg) and serum creatinine (1.82 vs. 1.86 mg/dl). There were no significant differences in the incidence of a 20% creatinine rise (23% vs. 25%) or in the change in serum creatinine (-0.05 vs. +0.05 mg/dl). There were no significant differences in the secondary end points of change in weight (-2.19 vs. -1.58 kg), intravenous furosemide (125 vs. 107 mg), discontinuation of the infusion due to hypotension (13% vs. 6%), or 30-day death/hospital readmission (33% vs. 25%). CONCLUSIONS: In this randomized, double-blind, placebo-controlled clinical trial, nesiritide had no impact on renal function in patients with acute decompensated heart failure. (BNP-CARDS trial; http://www.clinicaltrials.gov/ct/show/NCT00186329?order=1; NCT00186329).


Assuntos
Injúria Renal Aguda/tratamento farmacológico , Insuficiência Cardíaca/tratamento farmacológico , Testes de Função Renal , Injúria Renal Aguda/sangue , Idoso , Creatinina/sangue , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Feminino , Insuficiência Cardíaca/sangue , Humanos , Infusões Intravenosas , Injeções Intravenosas , Masculino , Peptídeo Natriurético Encefálico/administração & dosagem , Peptídeo Natriurético Encefálico/efeitos adversos
12.
Am J Cardiol ; 99(11): 1603-7, 2007 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-17531589

RESUMO

Cardiac allograft vasculopathy (CAV) is a progressive process involving the epicardial and microvascular coronary systems. The timing of the development of abnormalities in these 2 compartments and the correlation between changes in physiology and anatomy are undefined. The invasive evaluation of coronary artery anatomy and physiology with intravascular ultrasound, fractional flow reserve, coronary flow reserve, and the index of microcirculatory resistance (IMR) was performed in the left anterior descending coronary artery during 151 angiographic evaluations of asymptomatic heart transplant recipients from 0 to >5 years after heart transplantation (HT). There was no angiographic evidence of significant CAV, but during the first year after HT, fractional flow reserve decreased significantly (0.89 +/- 0.06 vs 0.85 +/- 0.07, p = 0.001), and percentage plaque volume derived by intravascular ultrasound increased significantly (15.6 +/- 7.7% to 22.5 +/- 12.3%, p = 0.0002), resulting in a significant inverse correlation between epicardial physiology and anatomy (r = -0.58, p <0.0001). The IMR was lower in these patients compared with those > or =2 years after HT (24.1 +/- 14.3 vs 29.4 +/- 18.8 units, p = 0.05), suggesting later spread of CAV to the microvasculature. As the IMR increased, fractional flow reserve increased (0.86 +/- 0.06 to 0.90 +/- 0.06, p = 0.0035 comparing recipients with IMRs < or =20 to those with IMRs > or =40), despite no difference in percentage plaque volume (21.0 +/- 11.2% vs 20.5 +/- 10.5%, p = NS). In conclusion, early after HT, anatomic and physiologic evidence of epicardial CAV was found. Later after HT, the physiologic effect of epicardial CAV may be less, because of increased microvascular dysfunction.


Assuntos
Vasos Coronários/patologia , Vasos Coronários/fisiopatologia , Transplante de Coração , Adulto , Análise de Variância , Velocidade do Fluxo Sanguíneo , Angiografia Coronária , Circulação Coronária , Estenose Coronária/diagnóstico por imagem , Estenose Coronária/fisiopatologia , Vasos Coronários/diagnóstico por imagem , Feminino , Humanos , Modelos Lineares , Masculino , Microcirculação , Pessoa de Meia-Idade , Período Pós-Operatório , Projetos de Pesquisa , Transplante Homólogo , Ultrassonografia de Intervenção , Resistência Vascular
13.
Pacing Clin Electrophysiol ; 30(3): 390-4, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17367359

RESUMO

BACKGROUND: As heart disease is increasingly recognized in women and as important studies have elucidated the benefit of implantable cardioverter defibrillators (ICDs) in patients with nonischemic cardiomyopathy (NICM), little is known regarding the effect of gender difference on arrhythmic risk in this population. We sought to determine if there are gender differences in arrhythmic risk and potential defibrillator benefit in patients with NICM. METHODS: The records of 767 consecutive patients who underwent ICD implant at the Stanford Medical Center from 1984 to 2002 were reviewed. Only patients with NICM were considered (n = 201, 26.2%). Of these, 140 patients had clinical follow-up information available. Baseline variables were examined, including age, baseline heart rate, ejection fraction, and medications. We evaluated the time to first shock as well as all-cause mortality in this patient population. Kaplan-Meier survival curves were plotted, a log-rank test was used to evaluate significance, and Cox-proportional hazards test was used for multivariate analysis. RESULTS: There were 88 (62.9%) men and 52 (37.1%) women. Between male and female patients, there were no significant differences in baseline mean age (54.8 +/- 1.9 years vs 53.1 +/- 2.3 years, respectively), ejection fraction (35.2 +/- 2.0% vs 33.3 +/- 2.3%, respectively), and mean left ventricular end-diastolic dimension (6.4 +/- 0.3 cm vs 5.9 +/- 0.2 cm, respectively). Mean follow-up time was 30.8 months. Thirty-two male patients (36.4 +/- 0.05%) received appropriate shocks compared with 20 female patients (38.5 +/- 0.07%). Mean time to the first appropriate shock was 11.9 +/- 3.9 months for male patients and 21.3 +/- 5.8 months for female patients (P = 0.2). Nineteen male patients (21.6 +/- 0.05%) died or received heart transplant during the follow-up period compared with 6 female patients (11.5 +/- 0.04%) (P = 0.11). CONCLUSION: Male and female patients with NICM who received ICDs had similar rate of appropriate shock and mortality. In this population gender does not appear to be an important risk factor for mortality or arrhythmic events.


Assuntos
Arritmias Cardíacas/mortalidade , Arritmias Cardíacas/prevenção & controle , Cardiomiopatias/mortalidade , Cardiomiopatias/terapia , Desfibriladores Implantáveis/estatística & dados numéricos , Cardioversão Elétrica/mortalidade , Medição de Risco/métodos , California/epidemiologia , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/mortalidade , Isquemia Miocárdica/terapia , Estudos Retrospectivos , Fatores de Risco , Distribuição por Sexo , Fatores Sexuais , Análise de Sobrevida , Taxa de Sobrevida
14.
Int J Cardiol ; 116(2): e48-50, 2007 Mar 20.
Artigo em Inglês | MEDLINE | ID: mdl-16930750

RESUMO

Spontaneous coronary artery dissection (SCAD) is a potentially life-threatening entity with a variety of clinical presentations. We report a patient who presented with chest pain and angiographic evidence of coronary dissection. Due to the rapid resolution of symptoms and benign-appearing nature of the dissection, no intervention was pursued and the patient was maintained on medical therapy. She represented 2 days later with substernal chest pain, dynamic EKG changes, positive cardiac biomarkers and a transient depression of her left ventricular function.


Assuntos
Dissecção Aórtica/complicações , Aneurisma Coronário/complicações , Disfunção Ventricular Esquerda/etiologia , Dissecção Aórtica/tratamento farmacológico , Fármacos Cardiovasculares/uso terapêutico , Aneurisma Coronário/tratamento farmacológico , Feminino , Humanos , Pessoa de Meia-Idade , Recidiva , Sístole , Disfunção Ventricular Esquerda/tratamento farmacológico
15.
J Clin Oncol ; 25(1): 43-9, 2007 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-17194904

RESUMO

PURPOSE: Incidental cardiac irradiation during treatment of thoracic neoplasms has increased risks for subsequent acute myocardial infarction or sudden cardiac death. Identifying patients who have a high risk for a coronary event may decrease morbidity and mortality. The objective of this study was to evaluate whether stress imaging can identify severe, unsuspected coronary stenoses in patients who had prior mediastinal irradiation for Hodgkin's disease. PATIENTS AND METHODS: We enrolled 294 outpatients observed at a tertiary care cancer treatment center after mediastinal irradiation doses 35 Gy for Hodgkin's disease who had no known ischemic cardiac disease. Patients underwent stress echocardiography and radionuclide perfusion imaging at one stress session. Coronary angiography was performed at the discretion of the physician. RESULTS: Among the 294 participants, 63 (21.4%) had abnormal ventricular images at rest, suggesting prior myocardial injury. During stress testing, 42 patients (14%) developed perfusion defects (n = 26), impaired wall motion (n = 8), or both abnormalities (n = 8). Coronary angiography showed stenosis 50% in 22 patients (55%), less than 50% in nine patients (22.5%), and no stenosis in nine patients (22.5%). Screening led to bypass graft surgery in seven patients. Twenty-three patients developed coronary events during a median of 6.5 years of follow-up, with 10 acute myocardial infarctions (two fatal). CONCLUSION: Stress-induced signs of ischemia and significant coronary artery disease are highly prevalent after mediastinal irradiation in young patients. Stress testing identifies asymptomatic individuals at high risk for acute myocardial infarction or sudden cardiac death.


Assuntos
Doença da Artéria Coronariana/diagnóstico , Doença de Hodgkin/radioterapia , Mediastino/efeitos da radiação , Radioterapia/efeitos adversos , Adulto , Estudos de Coortes , Angiografia Coronária/métodos , Estenose Coronária/diagnóstico , Ecocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Isquemia Miocárdica/diagnóstico , Risco , Fatores de Tempo
16.
J Am Coll Cardiol ; 48(12): 2397-409, 2006 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-17174176

RESUMO

While pharmaceutical innovation has been highly successful in reducing mortality in chronic heart failure, this has not been matched by similar success in decompensated heart failure syndromes. Despite outstanding issues over definitions and end points, we argue in this paper that an unprecedented wealth of pharmacologic innovation may soon transform the management of these challenging patients. Agents that target contractility, such as cardiac myosin activators and novel adenosine triphosphate-dependent transmembrane sodium-potassium pump inhibitors, provide inotropic support without arrhythmogenic increases in cytosolic calcium or side effects of more traditional agents. Adenosine receptor blockade may improve glomerular filtration and diuresis by exerting a direct beneficial effect on glomerular blood flow while vasopressin antagonists promote free water excretion without compromising renal function and may simultaneously inhibit myocardial remodeling. Urodilatin, the renally synthesized isoform of atrial natriuretic peptide, may improve pulmonary congestion via vasodilation and enhanced diuresis. Finally, metabolic modulators such as perhexiline may optimize myocardial energy utilization by shifting adenosine triphosphate production from free fatty acids to glucose, a unique and conceptually appealing approach to the management of heart failure. These advances allow optimism not only for the advancement of our understanding and management of decompensated heart failure syndromes but for the translational research effort in heart failure biology in general.


Assuntos
Cardiotônicos/uso terapêutico , Fármacos Cardiovasculares/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Natriuréticos/uso terapêutico , Antagonistas dos Receptores de Hormônios Antidiuréticos , Fator Natriurético Atrial/uso terapêutico , Miosinas Cardíacas/efeitos dos fármacos , Etiocolanolona/análogos & derivados , Etiocolanolona/uso terapêutico , Humanos , Fragmentos de Peptídeos/uso terapêutico , Perexilina/uso terapêutico , Antagonistas de Receptores Purinérgicos P1 , ATPase Trocadora de Sódio-Potássio/antagonistas & inibidores
17.
Nat Clin Pract Cardiovasc Med ; 3(11): 633-6, 2006 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17063168

RESUMO

BACKGROUND: A 28-year-old man presented at hospital with persistent pain in his chest and left arm, a paced rhythm on electrocardiography and elevated levels of cardiac enzymes. He was known to have patent foramen ovale and a dual-chamber pacemaker, which had been implanted following electrophysiological ablation to treat supraventricular tachycardia 3 years previously. The patient did not have a history of cardiovascular risk factors, recent travel, immobilization or clinical features of infection, and he was not taking any medication. INVESTIGATIONS: Electrocardiography, cardiac enzyme studies, coronary angiography and transthoracic echocardiography. DIAGNOSIS: Acute myocardial infarction, paradoxical coronary embolus and patent foramen ovale. MANAGEMENT: Coronary aspiration embolectomy and systemic anticoagulation.


Assuntos
Cateterismo Cardíaco , Vasos Coronários , Embolectomia/métodos , Embolia Paradoxal/terapia , Infarto do Miocárdio/terapia , Adulto , Anticoagulantes/uso terapêutico , Angiografia Coronária , Vasos Coronários/patologia , Vasos Coronários/cirurgia , Ecocardiografia Doppler em Cores , Eletrocardiografia , Embolia Paradoxal/etiologia , Embolia Paradoxal/patologia , Embolia Paradoxal/cirurgia , Comunicação Interatrial/complicações , Humanos , Masculino , Infarto do Miocárdio/etiologia , Infarto do Miocárdio/patologia , Infarto do Miocárdio/cirurgia , Marca-Passo Artificial/efeitos adversos , Resultado do Tratamento
18.
J Heart Lung Transplant ; 25(7): 765-71, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16818118

RESUMO

BACKGROUND: Investigating changes in coronary physiology that occur after cardiac transplantation has been challenging. Simultaneous and independent assessment of the epicardial artery by measuring fractional flow reserve (FFR) and of the microvasculature by calculating the index of microvascular resistance (IMR) with a single coronary pressure wire may be useful. METHODS: Twenty-five asymptomatic patients with normal coronary angiograms underwent FFR, thermodilution-derived IMR and coronary flow reserve (CFR) and intravascular ultrasound (IVUS) evaluation soon after cardiac transplantation and 1 year later. RESULTS: FFR significantly worsened (0.90 +/- 0.05 at baseline to 0.85 +/- 0.06 at 1 year, p = 0.004). FFR correlated strongly with percent plaque volume as measured by IVUS (r = -0.58, p < 0.0001). IMR improved significantly (29.2 +/- 15.9 at baseline to 19.3 +/- 7.6 units at 1 year, p = 0.007). CFR increased, but not significantly (2.6 +/- 1.4 at baseline to 3.2 +/- 1.2 at 1 year, p = not significant). Diabetes and donor heart ischemic time independently predicted baseline IMR. Treatment with rapamycin independently predicted FFR at 1 year. CONCLUSIONS: New coronary physiologic measures, FFR and IMR, show that epicardial artery physiology worsens and correlates with anatomic changes, whereas microvascular physiology improves during the first year after cardiac transplantation. CFR, the traditional method for evaluating coronary circulatory physiology, did not identify these changes.


Assuntos
Circulação Coronária , Vasos Coronários/fisiopatologia , Transplante de Coração/efeitos adversos , Microcirculação , Pericárdio/fisiopatologia , Resistência Vascular , Cateterismo Cardíaco , Angiografia Coronária , Vasos Coronários/diagnóstico por imagem , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Período Pós-Operatório , Termodiluição/métodos , Ultrassonografia de Intervenção
19.
Am Heart J ; 150(5): 977-82, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16290974

RESUMO

BACKGROUND: Mediastinal irradiation is known to cause cardiac disease, but its effect on left ventricular diastolic function is unknown. The purpose of this study was to determine the prevalence of diastolic dysfunction and its association with prognosis in asymptomatic patients after mediastinal irradiation. METHODS: We recruited 294 patients who had received at least 35 Gy to the mediastinum for treatment of Hodgkin disease. Each patient underwent resting echocardiography, stress echocardiography, and nuclear scintigraphy. Survival free from cardiac events was determined during 3.2 years of follow-up. RESULTS: The mean age of the included patients was 42 years, and 49% were male. Adequate measurements of diastolic function were obtained in 282 (97%) patients. Diastolic dysfunction was considered mild in 26 (9%) and moderate in 14 (5%). Exercise-induced ischemia was more common in patients with diastolic dysfunction (23%) than those with normal diastolic function (11%, P = .008). After adjustment for patient demographics, clinical characteristics, and radiation history, patients with diastolic dysfunction had worse event-free survival than patients with normal function (hazard ratio 1.66, 95% CI 1.06-2.4). CONCLUSIONS: There is a high prevalence of diastolic dysfunction in asymptomatic patients after mediastinal irradiation, and the presence of diastolic dysfunction is associated with stress-induced ischemia and a worse prognosis. Screening with Doppler echocardiography may be helpful in identifying patients at risk for subsequent cardiac events.


Assuntos
Diástole/efeitos dos fármacos , Mediastino/efeitos da radiação , Adulto , Feminino , Cardiopatias/epidemiologia , Cardiopatias/etiologia , Cardiopatias/fisiopatologia , Doença de Hodgkin/radioterapia , Humanos , Masculino , Pessoa de Meia-Idade
20.
J Heart Lung Transplant ; 24(8): 1163-5, 2005 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16102466

RESUMO

This study reports the development of lymphocytic myocarditis in a bilateral lung allograft recipient. A 23-year-old woman developed congestive heart failure and severe left ventricular dysfunction 32 months after a bilateral lung allograft for cystic fibrosis. She had taken oral acyclovir for infectious mononucleosis that was diagnosed 11 months previously. Her viral load for Epstein-Barr virus (EBV) increased, and an echocardiogram revealed a left ventricular ejection fraction of 25% and endomyocardial biopsy revealed lymphocytic myocarditis. She received valacyclovir (1 g x 3 times daily) and made a full recovery 6 months later.


Assuntos
Insuficiência Cardíaca/etiologia , Mononucleose Infecciosa/etiologia , Transplante de Pulmão/efeitos adversos , Miocardite/tratamento farmacológico , Miocardite/etiologia , Aciclovir/administração & dosagem , Aciclovir/análogos & derivados , Adulto , Antivirais/administração & dosagem , Biópsia por Agulha , Fibrose Cística/diagnóstico , Fibrose Cística/cirurgia , Feminino , Seguimentos , Humanos , Imuno-Histoquímica , Mononucleose Infecciosa/diagnóstico , Mononucleose Infecciosa/tratamento farmacológico , Transplante de Pulmão/métodos , Linfócitos/patologia , Miocardite/patologia , Medição de Risco , Índice de Gravidade de Doença , Resultado do Tratamento , Valaciclovir , Valina/administração & dosagem , Valina/análogos & derivados
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...